Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check5 days agoChange DetectedThe footer now displays Revision: v3.4.2, replacing Revision: v3.4.1.SummaryDifference0.0%

- Check13 days agoChange DetectedA minor revision update was added (Revision: v3.4.1) and the previous revision (v3.4.0) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check20 days agoChange DetectedGlossary visibility was added and QC metadata/revision text updated; these are display-only changes and do not modify study content.SummaryDifference0.2%

- Check27 days agoChange DetectedAdministrative updates to the study record dates and minor regulatory text removals were made; there were no changes to core content, eligibility criteria, outcomes, or study design. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedRevision: v3.3.4 has been added and the previous Revision: v3.3.3 has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check56 days agoChange DetectedLocations section reorganized to add California, Georgia, Massachusetts, Ohio, and Texas as locations and to remove the previous state blocks, with the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.